Synovial sarcoma

Originally thought to arise from synovial cells, this tumour probably arises from pluripotential mesenchymal cells capable of partial or aberrant epithelial differentaition24.

This tumour accounts for approximately 10% of all soft tissue sarcomas7 and commonly arises in the para-articular deep soft tissues of the extremities of young adults. It has also been identified in the head and neck area15,18,22,23 including the third ventricle25, thorax (mediastinum, pleura, heart, lung5, heart, chest wall, pharynx, larynx), abdominal wall17, retroperitoneum27,28, mesentry26, kidney16,20, prostate19,29, vulva21 and peritoneal cavity.

Synovial sarcomas show a specific chromosomal translocation, t(X:18)(p11.2;q11.2), which results in fusion of the SYT gene on the long arm of chromosome 18 with the SSX1, SSX2 or SSX4 gene on the short arm of the X chromosome. The transcript of the fusion gene can be demonstrated by reverse transcriptase-polymerase chain reaction in more than 90% of cases5,6 and may be identified from paraffin-embedded tissue by in situ hybridisation.

Variants

Rarely, synovial sarcoma may show extensive calcification and ossification2 or cartilage formation. The existence of a pure epithelial variant is controversial, but may be diagnosed on a deep seated soft tissue tumour in a patient who fails to declare an epithelial primary after several years4.

 

Immunohistochemistry

EMA

up to 90%, 1/126

Ca15.3

positive

low MW cytokeratins

60-70%

bcl-2

93%

S-100

30%3

CD30

rarely

CD99

48%

CD117

some

CNA.42

positive

CD34

negative

Microphthalmia transcription factor

negative

tyrosinase

negative

Cytokeratin 1

14/2210

Cytokeratin 5/6

9/3710

Cytokeratin 7

73/8110

Cytokeratin 8 / 18

88/8810

Cytokeratin 10

4/1810

Cytokeratin 13

15/638

Cytokeratin14

39/4410

Cytokeratin 19

53/533

Cytokeratin 20

0/61, 12/4510

vimentin

2/25, 1/126

desmin

1/126

SMA

0/25

Muscle-specific actin

0/25

CD34

0/25

b-catenin

44/447

   

A study of monophasic fibrous and poorly differentiated synovial sarcomas, with the diagnosis established by the presence of the translocations t(X:18)(p11.2;q11.2) has shown that reactivity for EMA, AE1/AE3 and E-cadherin, combined with negativity for CD34 is the most useful combination of markers for these problematic types of synovial sarcoma9.

The proliferative indices and expression of the pro-apoptotic factor bax are higher in the solid/glandular component than in the spindle cell component11. The latter shows a greater expression of the anti-apoptotic factor bcl-211. The SYT-SSX1 is associated with biphasic morphology13 and a higher proliferative index12.

 

solid-glandular component

spindle cell component

 

<10%

10-30%

>30%

<10%

10-30%

>30%

Ki67

2/1011

8/1011

0/1011

10/1011

0/1011

0/1011

bcl-2

6/1011

4/1011

0/1011

2/1011

3/1011

5/1011

AE1/AE3

0/1011

1/1011

9/1011

10/1011

0/1011

0/1011

Vimentin

9/1011

0/1011

1/1011

2/1011

4/1011

4/1011

bax

2/811

5/811

1/811

8/811

0/811

0/811

             

Differential diagnosis: see the immunohistochemistry of the differential diagnosis of spindle cell stromal tumours of the pleura. The t(X:18)(p11.2;q11.2) seems to have both specificity and sensitivity for synovial sarcoma and is extremely useful in cases of doubt

 Reference9

cytokeratin

EMA

 

S-100

CD99

bcl-2

 

MPNST

some, focally

some focally

50-70%

some focally

some focally

cellular Schwannoma

 

 

diffusely strongly

 

 

spindle cell melanoma

 

 

diffusely strongly

 

 

solitary fibrous tumour

 

 

 

positive

positive

giant cell angiofibroma

 

 

 

some

some

lipomatous haemangiopericytoma

 

 

 

some

some

sclerosing epithelioid fibrosarcoma

 

 

 

some

some

epithelioid sarcoma

positive

 

 

 

 

Ewing's sarcoma/PNET

positive

 

 

some

some

leiomyosarcoma

some

 

 

 

 

rhabdomyosarcoma

some

 

 

 

 

 

Prognosis

The five and ten year survival rates in one study were 68% and 41% respectively. Variables associated with an adverse outcome included tumour size >6.7 cm, poorly differentiated subtype, high nuclear atypia, mitotic count > 27/10 high-power fields, absence of stromal calcification, nuclear expression of b-catenin and Ki-67 (MIB-1) index > 27%7. A high proliferation rate and poor prognosis are associated with the SYT-SSX1 translocation14.

References

1 Miettinen M. Keratin 20: immunohistochemical marker for gastrointestinal, urothelial and Merkel cell carcinomas. Mod Pathol 1995;8:384-388.

2 Winnepenninckx V et al. Calcifying/ossifying synovial sarcoma shows t(X;18) with SSX2 involvement and mitochondrial calcification. Histopathology 2001;38:141-145.

3 Diagnostic histopathology of tumors. Edited by CDM Fletcher. 2nd edition. Churchill Livingstone. Page 1525.

4 Tajima, K., Fuyama, S., Yamaguchi, H., Ohrui, H., Suzuki, K., Akiba, J., Yahagi, A., Hayashi, T., Satoh, S., Katoh, T. Pure monophasic, epithelial synovial sarcoma without a spindle cell component Histopathology 1999;34:78-81.

5 Hisaoka, M., Hashimoto, H., Iwamasa, T., Ishikawa, K., Aoki, T. Primary synovial sarcoma of the lung: report of two cases confirmed by molecular detection of SYT-SSX fusion gene transcripts. Histopathology 1999;34:205-210

6 Guillou, L., Coindre, J., Gallagher, G., Terrier, P., Gebhard, S., de Saint Aubain Somerhausen, N., Michels, J., Jundt, G., Vince, D. R., Collin, F., Trassard, M., Le Doussal, V., Benhattar, J. Detection of the synovial sarcoma translocation t(X;18) (SYT;SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists. A molecular analysis of 221 mesenchymal tumors fixed in different fixatives. Human Pathol 2001;32:105-112.

7 Hasegawa, T., Yokoyama, R., Matsuno, Y., Shimoda, T., Hirohashi, S. Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Human Pathol 2001;32:257-263.

8 Diagnostic Immunohistochemistry edited by Professor D. J. Dabbs, page 60.

9 Pelmus, M., Guillou, L., Hostein, I., Sierankowski, G., Lussan, C. and Coindre, J.M. Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases. Am J Surg Pathol 2002;26:1434-40.

10 Chu, P. G. and L. M. Weiss (2002). "Keratin expression in human tissues and neoplasms." Histopathology 40(5): 403-39. (Summary data from multiple papers)

11 Lopes, J. M., J. M. Nesland, et al. (2002). "Differential Ki67 and bcl-2 immunoexpression in solid-glandular and spindle cell components of biphasic synovial sarcoma: a double immunostaining assessment with cytokeratin and vimentin." Histopathology 40(5): 464-71.

12 Inagaki, H., T. Nagasaka, et al. (2000). "Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma." Mod Pathol 13(5): 482-8.

13 dos Santos, N. R., D. R. de Bruijn, et al. (2001). "Molecular mechanisms underlying human synovial sarcoma development." Genes Chromosomes Cancer 30(1): 1-14.

14 Nilsson, G., B. Skytting, et al. (1999). "The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome." Cancer Res 59(13): 3180-4.

15 Amble FR, Olsen KD, Nascimento AG,Foote RL. Head and neck synovial cell sarcoma. Otolaryngol Head Neck Surg 1992; 107:631-7

16 Argani P, Faria PA, Epstein JI, et al. Primary renal synovial sarcoma: molecular and morphologic delineation of an entity previously included among embryonal sarcomas of the kidney. Am J Surg Pathol 2000; 24:1087-96

17 Fetsch JF,Meis JM. Synovial sarcoma of the abdominal wall. Cancer 1993; 72:469-77

18 Grayson W, Nayler SJ,Jena GP. Synovial sarcoma of the parotid gland. A case report with clinicopathological analysis and review of the literature. S Afr J Surg 1998; 36:32-4; discussion 34-5

19 Iwasaki H, Ishiguro M, Ohjimi Y, et al. Synovial sarcoma of the prostate with t(X;18)(p11.2;q11.2). Am J Surg Pathol 1999; 23:220-6

20 Kim DH, Sohn JH, Lee MC, et al. Primary synovial sarcoma of the kidney. Am J Surg Pathol 2000; 24:1097-104

21 Nielsen GP, Shaw PA, Rosenberg AE, Dickersin GR, Young RH,Scully RE. Synovial sarcoma of the vulva: a report of two cases. Mod Pathol 1996; 9:970-4

22 Ratnatunga N, Goodlad JR, Sankarakumaran N, Seimon R, Nagendran S,Fletcher CD. Primary biphasic synovial sarcoma of the orbit. J Clin Pathol 1992; 45:265-7

23 Shmookler BM, Enzinger FM,Brannon RB. Orofacial synovial sarcoma: a clinicopathologic study of 11 new cases and review of the literature. Cancer 1982; 50:269-76

24 Suster S,Moran CA. Primary synovial sarcomas of the mediastinum: a clinicopathologic, immunohistochemical, and ultrastructural study of 15 cases. Am J Surg Pathol 2005; 29:569-78

25 Kleinschmidt-DeMasters BK, Mierau GW, Sze CI, et al. Unusual dural and skull-based mesenchymal neoplasms: a report of four cases. Hum Pathol 1998; 29:240-5

26 Helliwell TR, King AP, Raraty M, et al. Biphasic synovial sarcoma in the small intestinal mesentery. Cancer 1995; 75:2862-6

27 Miyashita T, Imamura T, Ishikawa Y, et al. Primary retroperitoneal synovial sarcoma. Intern Med 1994; 33:692-6

28 Shmookler BM Retroperitoneal synovial sarcoma. A report of four cases. Am J Clin Pathol 1982; 77:686-91

29 Pan CC,Chang YH. Primary synovial sarcoma of the prostate. Histopathology 2006; 48:321-3

This page last revised 27.6.2005.

©SMUHT/PW Bishop